MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

 MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

MatriSys Report Results of MSB-0221 in P-I study for the Topical Treatment of Atopic Dermatitis

Shots:

  • The P-I trial involves assessing MSB-0221 (ShA9) or vehicle applied topically on forearm skin in 54 adults with staphylococcus aureus-positive AD for 1week
  • The expression of mRNA for psmα was inhibited from S. aureus isolated from all participants while the correlation was observed within 7days b/w improvement in local eczema severity and killing of S. aureus
  • In general, the results showed the safety and potential benefits of bacteria to treat chronic skin diseases. Additionally, the company plans to conduct a P-II clinical trial that will evaluate MSB-0221 vs PBO in 150 patients over a 12wks. treatment period to treat AD

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Owler

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post